Novartis to spend over US$500m on new biotechnology plant in Tuas
Swiss pharmaceutical giant Novartis will pump over US$500 million into building a new biotechnology plant in Tuas, it said on Wednesday.
The plant uses cell cultures to produce drugs, which could be used to treat autoimmune disorders, respiratory diseases and cancer, among others. It will be located next to Novartis' current pharmaceutical production plant.
Making drugs from cell cultures rather than from chemicals is known as biologics, a field that is expected to grow.
Novartis said this investment would support its "growing pipeline" of biologics,which represents a quarter of its current clinical pharmaceutical research pipeline.